Clinical Trial Update: Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluating subcutaneous amlitelimab in adults with moderate-to-severe hidradenitis suppurativa has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Hidradenitis | Phase 2 | Status: TERMINATED